Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
- DOI
- 10.1016/j.ygyno.2024.11.004
- Published
- 2025-01
- Container
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ygyno.2024.11.004,
title = {Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer},
author = {Katherine Elizabeth Francis and Sandy Simon and Val Gebski and Florence Joly and Jonathan A. Ledermann and Richard T. Penson and Amit M. Oza and Jacob Korach and Nuria Lainez and Sabrina Chiara Cecere and Giulia Tasca and Martina Gropp-Meier and Keiichi Fujiwara and Elizabeth S. Lowe and Michael Friedlander and Eric Pujade-Lauraine and Chee Khoon Lee},
year = {2025},
journal = {Gynecologic Oncology},
doi = {10.1016/j.ygyno.2024.11.004},
url = {https://doi.org/10.1016/j.ygyno.2024.11.004}
}RIS
TY - JOUR TI - Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer AU - Katherine Elizabeth Francis AU - Sandy Simon AU - Val Gebski AU - Florence Joly AU - Jonathan A. Ledermann AU - Richard T. Penson AU - Amit M. Oza AU - Jacob Korach AU - Nuria Lainez AU - Sabrina Chiara Cecere AU - Giulia Tasca AU - Martina Gropp-Meier AU - Keiichi Fujiwara AU - Elizabeth S. Lowe AU - Michael Friedlander AU - Eric Pujade-Lauraine AU - Chee Khoon Lee PY - 2025 JO - Gynecologic Oncology DO - 10.1016/j.ygyno.2024.11.004 UR - https://doi.org/10.1016/j.ygyno.2024.11.004 ER -
APA
Francis, K. E., Simon, S., Gebski, V., Joly, F., Ledermann, J. A., Penson, R. T., Oza, A. M., Korach, J., Lainez, N., Cecere, S. C., Tasca, G., Gropp-Meier, M., Fujiwara, K., Lowe, E. S., Friedlander, M., Pujade-Lauraine, E., & Lee, C. K. (2025). Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2024.11.004
Source records
- crossref · retrieved 2026-09-25T22:54:31.057Z